Wire · regulatory
FDA again turns back Capricor Duchenne cell therapy
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 21 November 2026 · Fusion42 review
The FDA has rejected Capricor's cell therapy for Duchenne muscular dystrophy for a second time due to serious data integrity violations that compromised the study findings.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 12 Nov 2026 and 21 Nov 2026.
◆ ◆ The Wire takeaway
FDA enforcement is tightening on data integrity in drug trials, forcing you to rigorously audit trial data if you want a chance at approval in rare disease therapies.
◆ Coverage
7 sources · first reported 12 Nov 2026 · latest 21 Nov 2026
◆ Related on Wire
◆ Topics
Biotechfdaduchenne-muscular-dystrophycell-therapydata-integrityregulatory-rejection